Page 3 - தேசிய உட்செலுத்துதல் மையம் சங்கம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ Second Phase 3 trial undertaken in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infection Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive data from a Phase 3 trial (2069B) of recently infected asymptomatic COVID-19 patients, evaluating REGEN-COV™ (casirivimab with imdevimab) 1,200 mg administered via subcutaneous (SC) administration. REGEN-COV reduced the overall risk of progressing to symptomatic COVID-19 by 31% (primary endpoint), and by 76% after the third day. The trial also demonstrated that REGEN-COV shortened symptom duration and markedly reduced viral levels. The Phase 3 trial is the second to report results today, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The trial enrolled

United kingdomUnited statesSarah cornhillGeorged yancopoulosRegeneron velocimmuneVesna tosicNational institute of allergyRegeneron velocimmune technologyTeva pharmaceutical industries ltdDepartment of healthHospital of the university pennsylvaniaRegeneron pharmaceuticals incBiomedical advanced researchNational institutes of healthRegeneron genetics centerHuman services